JP2021517457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021517457A5 JP2021517457A5 JP2020548645A JP2020548645A JP2021517457A5 JP 2021517457 A5 JP2021517457 A5 JP 2021517457A5 JP 2020548645 A JP2020548645 A JP 2020548645A JP 2020548645 A JP2020548645 A JP 2020548645A JP 2021517457 A5 JP2021517457 A5 JP 2021517457A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- amino acid
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022143428A JP7447208B2 (ja) | 2018-03-12 | 2022-09-09 | 抗体 |
| JP2024027970A JP7791229B2 (ja) | 2018-03-12 | 2024-02-28 | 抗体 |
| JP2025245068A JP2026041981A (ja) | 2018-03-12 | 2025-12-11 | 抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18161293.8 | 2018-03-12 | ||
| EP18161293 | 2018-03-12 | ||
| EP18175347 | 2018-05-31 | ||
| EP18175347.6 | 2018-05-31 | ||
| PCT/EP2019/056197 WO2019175198A2 (en) | 2018-03-12 | 2019-03-12 | Antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143428A Division JP7447208B2 (ja) | 2018-03-12 | 2022-09-09 | 抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517457A JP2021517457A (ja) | 2021-07-26 |
| JP2021517457A5 true JP2021517457A5 (enExample) | 2021-10-07 |
| JP7209008B2 JP7209008B2 (ja) | 2023-01-19 |
Family
ID=65729373
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548645A Active JP7209008B2 (ja) | 2018-03-12 | 2019-03-12 | 抗体 |
| JP2022143428A Active JP7447208B2 (ja) | 2018-03-12 | 2022-09-09 | 抗体 |
| JP2024027970A Active JP7791229B2 (ja) | 2018-03-12 | 2024-02-28 | 抗体 |
| JP2025245068A Pending JP2026041981A (ja) | 2018-03-12 | 2025-12-11 | 抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143428A Active JP7447208B2 (ja) | 2018-03-12 | 2022-09-09 | 抗体 |
| JP2024027970A Active JP7791229B2 (ja) | 2018-03-12 | 2024-02-28 | 抗体 |
| JP2025245068A Pending JP2026041981A (ja) | 2018-03-12 | 2025-12-11 | 抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US20200277397A1 (enExample) |
| EP (1) | EP3765493A2 (enExample) |
| JP (4) | JP7209008B2 (enExample) |
| KR (1) | KR20200130723A (enExample) |
| CN (2) | CN120795158A (enExample) |
| AU (2) | AU2019233523B2 (enExample) |
| BR (1) | BR112020018490A2 (enExample) |
| CA (1) | CA3093745A1 (enExample) |
| CL (1) | CL2020002326A1 (enExample) |
| CO (1) | CO2020012524A2 (enExample) |
| CR (3) | CR20250347A (enExample) |
| EC (1) | ECSP20063690A (enExample) |
| IL (1) | IL277030A (enExample) |
| MA (1) | MA52152A (enExample) |
| MX (7) | MX2020009379A (enExample) |
| PE (1) | PE20210339A1 (enExample) |
| PH (1) | PH12020551447A1 (enExample) |
| SA (3) | SA523440622B1 (enExample) |
| SG (1) | SG11202008399QA (enExample) |
| WO (1) | WO2019175198A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3322727T3 (pl) | 2015-07-15 | 2026-05-11 | Genmab A/S | Humanizowane lub chimeryczne przeciwciała cd3 |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| CR20250347A (es) | 2018-03-12 | 2025-09-23 | Genmab As | ANTICUERPOS QUE SE UNEN A 5T4 (Divisional 2020-0463) |
| WO2021048423A1 (en) * | 2019-09-12 | 2021-03-18 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
| WO2022056354A1 (en) * | 2020-09-11 | 2022-03-17 | Actinium Pharmaceuticals, Inc. | Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers |
| RS66868B1 (sr) | 2021-01-28 | 2025-06-30 | Regeneron Pharma | Kompozicije i postupci za lečenje sindroma oslobađanja citokina |
| WO2022234570A1 (en) * | 2021-05-04 | 2022-11-10 | Immunorizon Ltd. | Anti-5t4 antibodies and uses thereof |
| US20230220106A1 (en) * | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| CA3247475A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR THE DESTRUCTION OF UNIVERSAL TUMOR CELLS |
| JP2025537193A (ja) * | 2022-11-08 | 2025-11-14 | フェインズ セラピューティクス，インコーポレーテッド | 抗５ｔ４抗体及びその使用 |
| JP2026506095A (ja) | 2023-02-17 | 2026-02-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃｄ３／ｔａａ二重特異性抗体に応答する誘導ｎｋ細胞 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| AU747602B2 (en) | 1997-06-04 | 2002-05-16 | Oxford Biomedica (Uk) Limited | Vector |
| CA2361421A1 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| CN1423660A (zh) | 1999-11-18 | 2003-06-11 | 牛津生物医学（英国）有限公司 | 抗体 |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| GB0126378D0 (en) | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
| EP2314629B2 (en) | 2002-07-18 | 2022-11-16 | Merus N.V. | Recombinant production of mixtures of antibodies |
| US20060088522A1 (en) | 2004-09-10 | 2006-04-27 | Wyeth | Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugates |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| NZ596295A (en) | 2006-03-10 | 2013-01-25 | Wyeth Corp | Anti-5T4 antibodies and uses thereof |
| CN103073639A (zh) | 2006-03-17 | 2013-05-01 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| CN104497143B (zh) | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
| CA2691434C (en) | 2007-06-21 | 2020-07-21 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| ES2733067T3 (es) | 2008-12-19 | 2019-11-27 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| AU2010245011B2 (en) | 2009-04-27 | 2015-09-03 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| GB0918383D0 (en) | 2009-10-20 | 2009-12-02 | Cancer Rec Tech Ltd | Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| CA3051311A1 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
| RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
| RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| WO2013041687A1 (en) * | 2011-09-23 | 2013-03-28 | Amgen Research (Munich) Gmbh | Bispecific binding molecules for 5t4 and cd3 |
| DK2771364T3 (da) | 2011-10-27 | 2019-08-19 | Genmab As | Fremstilling af heterodimere proteiner |
| US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
| WO2014137931A1 (en) | 2013-03-06 | 2014-09-12 | Imaginab, Inc. | Antigen binding constructs to 5t4 |
| KR102363220B1 (ko) | 2013-07-05 | 2022-02-15 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| WO2015155345A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
| WO2016022939A1 (en) * | 2014-08-08 | 2016-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies specific for 5t4 and methods of their use |
| CA2970986C (en) | 2014-12-19 | 2021-10-26 | Biotecnol Limited | Fusion protein comprising three binding domains to 5t4 and cd3 |
| PL3322727T3 (pl) * | 2015-07-15 | 2026-05-11 | Genmab A/S | Humanizowane lub chimeryczne przeciwciała cd3 |
| CN113862300A (zh) | 2015-10-29 | 2021-12-31 | 豪夫迈·罗氏有限公司 | 具有共同轻链的转基因兔 |
| EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| AU2016358854B2 (en) * | 2015-11-24 | 2023-02-02 | Byondis B.V. | Anti-5T4 antibodies and antibody-drug conjugates |
| CN110698560B (zh) * | 2015-12-24 | 2021-11-26 | 凯惠科技发展(上海)有限公司 | 一种tpbg抗体及其制备方法、其偶联物和应用 |
| WO2017182672A1 (en) * | 2016-04-22 | 2017-10-26 | Alligator Bioscience Ab | Novel bispecific polypeptides against cd137 |
| CN108285487B (zh) | 2017-01-08 | 2021-02-19 | 浙江昭华生物医药有限公司 | 抗5t4抗体-药物偶联物及其应用 |
| AU2018235130B2 (en) | 2017-03-15 | 2023-12-07 | Oxford Biomedica (Uk) Limited | Method |
| EP3608335A4 (en) | 2017-04-05 | 2020-04-29 | XDCExplorer (Shanghai) Co., Ltd. | HUMANIZED ANTI-TPBG ANTIBODY, PRODUCTION METHOD THEREFOR, CONJUGATE THEREOF AND APPLICATIONS |
| IL272103B2 (en) | 2017-07-20 | 2024-10-01 | Aptevo Res & Development Llc | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer |
| WO2019109047A1 (en) | 2017-12-01 | 2019-06-06 | Fred Hutchinson Cancer Research Center | Binding proteins specific for 5t4 and uses thereof |
| SG11202007572VA (en) | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| CR20250347A (es) | 2018-03-12 | 2025-09-23 | Genmab As | ANTICUERPOS QUE SE UNEN A 5T4 (Divisional 2020-0463) |
| WO2021048423A1 (en) * | 2019-09-12 | 2021-03-18 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
-
2019
- 2019-03-12 CR CR20250347A patent/CR20250347A/es unknown
- 2019-03-12 JP JP2020548645A patent/JP7209008B2/ja active Active
- 2019-03-12 WO PCT/EP2019/056197 patent/WO2019175198A2/en not_active Ceased
- 2019-03-12 KR KR1020207028911A patent/KR20200130723A/ko not_active Ceased
- 2019-03-12 BR BR112020018490-0A patent/BR112020018490A2/pt unknown
- 2019-03-12 MX MX2020009379A patent/MX2020009379A/es unknown
- 2019-03-12 SG SG11202008399QA patent/SG11202008399QA/en unknown
- 2019-03-12 MA MA052152A patent/MA52152A/fr unknown
- 2019-03-12 AU AU2019233523A patent/AU2019233523B2/en active Active
- 2019-03-12 CR CR20200463A patent/CR20200463A/es unknown
- 2019-03-12 EP EP19710414.4A patent/EP3765493A2/en active Pending
- 2019-03-12 CA CA3093745A patent/CA3093745A1/en active Pending
- 2019-03-12 PE PE2020001384A patent/PE20210339A1/es unknown
- 2019-03-12 CN CN202510716554.XA patent/CN120795158A/zh active Pending
- 2019-03-12 CR CR20250348A patent/CR20250348A/es unknown
- 2019-03-12 CN CN201980025412.1A patent/CN111971298B/zh active Active
-
2020
- 2020-03-09 US US16/813,167 patent/US20200277397A1/en not_active Abandoned
- 2020-08-31 IL IL277030A patent/IL277030A/en unknown
- 2020-09-08 SA SA523440622A patent/SA523440622B1/ar unknown
- 2020-09-08 SA SA520420109A patent/SA520420109B1/ar unknown
- 2020-09-08 CL CL2020002326A patent/CL2020002326A1/es unknown
- 2020-09-08 SA SA523440623A patent/SA523440623B1/ar unknown
- 2020-09-09 MX MX2025003353A patent/MX2025003353A/es unknown
- 2020-09-09 MX MX2025003351A patent/MX2025003351A/es unknown
- 2020-09-09 MX MX2025003350A patent/MX2025003350A/es unknown
- 2020-09-09 MX MX2025003356A patent/MX2025003356A/es unknown
- 2020-09-09 MX MX2025003354A patent/MX2025003354A/es unknown
- 2020-09-09 MX MX2025003349A patent/MX2025003349A/es unknown
- 2020-09-11 PH PH12020551447A patent/PH12020551447A1/en unknown
- 2020-10-07 EC ECSENADI202063690A patent/ECSP20063690A/es unknown
- 2020-10-07 CO CONC2020/0012524A patent/CO2020012524A2/es unknown
- 2020-10-22 US US17/077,376 patent/US11008399B2/en active Active
-
2021
- 2021-04-12 US US17/228,023 patent/US11130819B2/en active Active
- 2021-06-21 US US17/353,087 patent/US11970544B2/en active Active
-
2022
- 2022-09-09 JP JP2022143428A patent/JP7447208B2/ja active Active
-
2024
- 2024-02-28 JP JP2024027970A patent/JP7791229B2/ja active Active
- 2024-03-26 US US18/617,483 patent/US20240392032A1/en active Pending
-
2025
- 2025-12-11 JP JP2025245068A patent/JP2026041981A/ja active Pending
-
2026
- 2026-04-07 AU AU2026202570A patent/AU2026202570A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534779A (ja) | 抗体構築物がプレロードされた凍結保存ｎｋ細胞 | |
| JP2020504171A (ja) | 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| EP3882276A1 (en) | Bispecific antibody, preparation method therefor and application thereof | |
| NZ791623A (en) | Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof | |
| WO2020114478A1 (zh) | Cd3抗体及其药物用途 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2018531219A (ja) | Ｐｄ−ｌ１抗体 | |
| JP2023517753A5 (enExample) | ||
| WO2020114479A1 (zh) | 多特异性蛋白分子 | |
| JP2023513200A (ja) | 抗ｃｄ３および抗ｃｄ１２３二重特異性抗体およびその使用 | |
| CN112166125B (zh) | 全人源的抗lag-3抗体及其应用 | |
| KR20230074192A (ko) | 인간 cd3 엡실론에 결합하는 신규의 인간 항체 | |
| CN121758618A (zh) | Pd1和vegfr2双结合剂 | |
| CN112771075A (zh) | 结合至cd33和cd3的双特异性抗体构建体的延长施用 | |
| US20230312709A1 (en) | Antibody targeting CD47 and application thereof | |
| CN119095873A (zh) | 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合 | |
| CN119060184B (zh) | 抗rage抗体及其应用 | |
| WO2024012434A1 (en) | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| EP4703384A1 (en) | Bispecific antibody targeting g protein-coupled receptor | |
| US20240376208A1 (en) | Duplexbodies | |
| CN115368457A (zh) | 抗tigit抗体及其用途 | |
| Zettlitz et al. | Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70) | |
| JP2022547135A (ja) | 増強されたプロテインｌ捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法 | |
| CN119371542B (zh) | 抗rage抗体及其应用 | |
| JP7844430B2 (ja) | 抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体 |